Results 51 to 60 of about 46,899 (191)

Cardiotoxicity of BRAF/MEK inhibitors

British Journal of Pharmacology, EarlyView.
Abstract Rapidly accelerated fibrosarcoma type B/B‐Raf proto‐oncogene, serine/threonine kinase (BRAF) and mitogen‐activated protein kinase (MEK) inhibitors have transformed outcomes in cancer therapy, particularly in melanoma. However, cardiovascular toxicities are increasingly recognized in real‐world clinical practice.
Katharina Seuthe, Valerie Lohner, Kevin Terre, Thomas Riffelmacher, Roman Pfister   +4 more
wiley   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Helicobacter pylori infection and expressions of EGF, EGFR and c-erbB-2 proteins in gastric carcinoma.

Folia Histochemica et Cytobiologica, 2010
The family of epidermal growth factor (EGF, EGFR, c-erbB-2) plays a pivotal role in gastric cancer progression, invasion and metastasizing. Helicobacter pylori infection is known to contribute significantly to the formation and progression of gastric ...
Andrzej Kemona, Katarzyna Guzińska-Ustymowicz, Anna Pryczynicz, Jolanta Czyzewska   +3 more
doaj   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

British Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß, Paul Goerke, Malte Kelm, Amin Polzin   +3 more
wiley   +1 more source

c-erbB-3 [PDF]

The Journal of Cell Biology, 2002
c-erbB receptors are usually located in cell membranes and are activated by extracellular binding of EGF-like growth factors. Unexpectedly, using immunofluorescence we found high levels of c-erbB-3 within the nuclei of MTSV1-7 immortalized nonmalignant human mammary epithelial cells.
Martin Offterdinger, Christian Schöfer, Klara Weipoltshammer, Thomas W. Grunt   +3 more
openaire   +1 more source

Membranous Levels of C-Erbb-2 Oncoprotein in Gastric Cancer: Their Relationship with Clinicopathological Parameters and Their Prognostic Significance

The International Journal of Biological Markers, 2004
Background The protein encoded by the c-erbB-2 gene is a membrane receptor expressed in a variety of solid human cancers and directly related to poor prognosis.
F.J. Vizoso, M.D. Corte, A. Alvarez, I. García, J.M. del Casar, M. Bongera, L.O. Gonzílez, J.L. García-Muñiz, M.T. Allende   +8 more
doaj   +1 more source

New Treatment Strategy and Future Research Direction for BRAF‐Mutated Cancer

Cancer Science, EarlyView.
Treatment with BRAF inhibitor plus MEK inhibitor is currently used in BRAF‐mutated various malignancies except colorectal cancer, and treatments with BRAF and/or MEK inhibitors and anti‐EGFR antibody are used in BRAF‐mutated colorectal cancer. Despite recent advances in BRAF‐targeted therapies, their efficacy is still limited.
Masanobu Takahashi, Sakura Hiraide Taniguchi, Yuya Yoshida   +2 more
wiley   +1 more source

Insider Influence on ErbB Activity [PDF]

Cell, 2010
The receptor tyrosine kinase ErbB is activated by ligand-induced dimerization, leading to transphosphorylation of the cytoplasmic kinase domains. Bill et al. (2010) now demonstrate that transphosphorylation can be modulated from within the cell by the cytoplasmic protein cytohesin, providing new insights into ErbB-dependent processes during normal ...
openaire   +2 more sources

Preliminary study of p53 and c-erbB-2 expression in gallbladder cancer in Indian patients

BMC Cancer, 2006
Background The inactivation of the tumour suppressor gene and activation of the proto-oncogene are the key steps in the development of the human cancer. The p53 and c-erbB-2 are the best examples of it.
Singh Usha, Garbyal RS, Tewari Mallika, Chaube Amita, Shukla Hari S   +4 more
doaj   +1 more source

Maternal obesity during lactation as a hypertensive cardiovascular risk factor in the offspring

Experimental Physiology, EarlyView.
Abstract Maternal obesity is a major public health concern, with growing evidence supporting its role in the developmental programming of cardiometabolic disease. Although prenatal mechanisms have been investigated extensively, the contribution of lactation as a postnatal window of cardiovascular (CV) programming remains insufficiently understood ...
Gabriela Arenas, Cristián A. Amador, Susana Contreras‐Duarte   +2 more
wiley   +1 more source